Globus Medical Cash on Hand 2010-2023 | GMED

Globus Medical cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Globus Medical cash on hand for the quarter ending March 31, 2023 was $0.504B, a 6.57% increase year-over-year.
  • Globus Medical cash on hand for 2022 was $0.446B, a 0.59% increase from 2021.
  • Globus Medical cash on hand for 2021 was $0.443B, a 3.91% increase from 2020.
  • Globus Medical cash on hand for 2020 was $0.427B, a 37% increase from 2019.
Globus Medical Annual Cash on Hand
(Millions of US $)
2022 $446
2021 $443
2020 $427
2019 $311
2018 $340
2017 $374
2016 $291
2015 $307
2014 $252
2013 $239
2012 $212
2011 $143
2010 $112
2009 $
Globus Medical Quarterly Cash on Hand
(Millions of US $)
2023-03-31 $504
2022-12-31 $446
2022-09-30 $405
2022-06-30 $408
2022-03-31 $473
2021-12-31 $443
2021-09-30 $553
2021-06-30 $460
2021-03-31 $404
2020-12-31 $427
2020-09-30 $410
2020-06-30 $317
2020-03-31 $277
2019-12-31 $311
2019-09-30 $278
2019-06-30 $240
2019-03-31 $321
2018-12-31 $340
2018-09-30 $373
2018-06-30 $361
2018-03-31 $369
2017-12-31 $374
2017-09-30 $338
2017-06-30 $313
2017-03-31 $327
2016-12-31 $291
2016-09-30 $258
2016-06-30 $336
2016-03-31 $329
2015-12-31 $307
2015-09-30 $264
2015-06-30 $224
2015-03-31 $237
2014-12-31 $252
2014-09-30 $299
2014-06-30 $276
2014-03-31 $281
2013-12-31 $239
2013-09-30 $213
2013-06-30 $161
2013-03-31 $162
2012-12-31 $212
2012-09-30 $195
2012-06-30 $166
2012-03-31 $159
2011-12-31 $143
2011-09-30
2011-06-30
2011-03-31
2010-12-31 $112
2009-12-31
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $5.519B $0.759B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $200.336B 24.71
Edwards Lifesciences (EW) United States $51.668B 34.09
Alcon (ALC) Switzerland $38.531B 34.94
STERIS (STE) Ireland $19.969B 24.66
Fresenius Medical Care AG KGaA (FMS) Germany $12.634B 14.07
Penumbra (PEN) United States $12.021B 766.44
Teleflex (TFX) United States $10.964B 17.62
Glaukos (GKOS) United States $2.836B 0.00
Integer Holdings (ITGR) United States $2.750B 20.81
Paragon 28 (FNA) United States $1.497B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.144B 14.77
Nevro (NVRO) United States $0.982B 0.00
Artivion (AORT) United States $0.604B 369.25